Gyre Therapeutics vs Zevra Therapeutics
Gyre Therapeutics reported revenue of $117 million in fiscal 2025, about the same as Zevra Therapeutics' $106 million in fiscal 2025. Gyre Therapeutics' revenue grew 10.2% in its latest year, and Zevra Therapeutics' grew 350.9%. Gyre Therapeutics had an operating margin of 9.8%, against -59.1% at Zevra Therapeutics. Free cash flow was −$0 million at Gyre Therapeutics and −$2 million at Zevra Therapeutics.
Side by side
| Gyre Therapeutics | Zevra Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $117M | $106M |
| Revenue growth | 10.2% | 350.9% |
| Revenue growth a year, last 5 years | 41.0% | 51.6% |
| Gross margin | 95.3% | — |
| Operating margin | 9.8% | −59.1% |
| Net margin | 8.5% | 78.2% |
| Free cash flow | −$0M | −$2M |
| Free cash flow margin | −0.1% | −2.3% |
| Return on capital | 9.7% | −218.8% |
| Net debt to EBITDA | −3.8x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.9% | 23.8% |
| Last close | $4.52 | $9.07 |
| P/E at the last close | — | 7.6× |
| Insider trades, last 12 months | sold $952,874 | sold $2.3 million |
| Piotroski F-score | 4 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Gyre TherapeuticsZevra Therapeutics
Operating margin
Percent of revenue
Gyre TherapeuticsZevra Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gyre TherapeuticsZevra Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gyre Therapeutics and Zevra Therapeutics pages.